Radiosensitizers with Hyperfractionation in Radiotherapy

  • C. Rimondi
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 43)


The use of misonidazole in radiotherapy for the treatment of cancer confronts the therapist with the problem of choosing how to relate the administration schedules of the drug with the radiation schedule (1). He must decide whether it is advisable to keep the usual dose-fraction schedules — for which tolerance is well known -or whether these schedules can be changed in order to exploit in the best way possible the radiosensitizing effect of this drug on the hypoxic cells present in tumours.


Malignant Glioma Hyperbaric Oxygen Bladder Carcinoma Hypoxic Cell Conventional Fractionation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. E. Adams, J. Denekamp and J. F. Fowler, Biological basis of sensitization by hypoxic cell radiosensitizers, Chemotherapy Vol.7, K. Hellmann and T. A. Connors, eds., Plenum Press, New York and London (1977).Google Scholar
  2. 2.
    J. R. Glassburn, L. W. Brady and H.P. Plenk, Hyperbaric oxygen in radiation therapy, Cancer 39:751 (1977).PubMedCrossRefGoogle Scholar
  3. 3.
    S. Dische, Hyperbaric oxygen: the MRC trials and their clinical significance, Brit. J. Radiol., 51:888 (1978).PubMedCrossRefGoogle Scholar
  4. 4.
    T. L. Phillips, Design of clinical trials for hypoxic cell sensitizers and radioprotectors in Conference on combined modality cancer treatment: radiation sensitizers and protectors, Key Biscayne, Florida, Oct.3–9, Abstracts, p.5 (1979).Google Scholar
  5. 5.
    S. Dische, Hypoxic cell sensitizers in radiotherapy, Int. J. Radiat. Oncol. Biol. Phys., 4:157 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    T. H. Wasserman, J. A. Stetz and T. L. Phillips, Clinical trials of misonidazole in the United States, Cancer Clin. Trials, 3 (1980) in press.Google Scholar
  7. 7.
    L. Revesz and B. Littbrand, Variation of the oxygen enhancement ratio at different X-ray level and its possible significance in “Advances in radiation research biology and medicine”Google Scholar
  8. 8.
    B. Littbrand and F. Edsmyr, Preliminary results of bladder carcinoma irradiated with low individual doses and a high total dose, Int. J. Radiat. Oncol. Biol. Phys. 1:1059 (1976).PubMedCrossRefGoogle Scholar
  9. 9.
    C. Rimondi and L. Busutti, Trattamento radiante di pazienti affetti da carcinoma vescicale (T3 NX MO) con tre sedute gionaliere in “Radiobiologia dei Tumori” EMSI (1978).Google Scholar
  10. 10.
    EORTC (Cooperative group of radiotherapy) Pilot study of the feasibility of a combination of daily multifractionation radiotherapy and misonidazole in the treatment of high grade malignant gliomas. Personal communication (1979).Google Scholar
  11. 11.
    NCOG: Protocol No. 6G91.Google Scholar
  12. 12.
    G. Arcangeli, F. Mauro, D. Morelli and C. Nervi, Multiple daily fractionation in radiotherapy: biological rationale and preliminary clinical experiences. Eur. J. Cancer, 15:1077 (1979) .PubMedCrossRefGoogle Scholar
  13. 13.
    EORTC (Cooperative group of radiotherapy) Protocol 22801, Pilot study on the combination of daily multifraction radiotherapy and misonidazole in the treatment of advanced head and neck cancer. Personal communication (1979).Google Scholar
  14. 14.
    EORTC (Cooperative group of radiotherapy) Randomized clinical trial on the influence of misonidazole in association with split course radiotherapy for epidermoid carcinoma of the bronchus. Personal communication (1979).Google Scholar
  15. 15.
    MRC (Cancer therapy committee) A study of misonidazole in conjunction with radiotherapy for the treatment of stage III carcinoma of the uterine cervix. Personal communication (1979).Google Scholar
  16. 16.
    EORTC: Protocol Ca. uterine cervix, stage III exclud. ETLA stage IV in association with misonidazole. Personal communication (1979).Google Scholar
  17. 17.
    G. Wiernik et al., Sixth interim progress report of the British Institute of Radiology fractionation study of 3F/week versus 5F/week in radiotherapy of the laryngo-pharynt, Brit. J. Radiol., 51:241 (1978).PubMedCrossRefGoogle Scholar
  18. 18.
    J. D. Cox, R. W. Byhardt, R. Komaki and M. Greenberg, Reduced fractionation and the potential of hypoxic cell sensitizers in irradiation of malignant epithelial tumours, Int. J. Radiat. Oncol. Biol. Phys. 6:37 (1980).PubMedCrossRefGoogle Scholar
  19. 19.
    E. R. Watson, K. E. Hainan, S. Dische, M. I. Saunders and I.S. Cade, Hyperbaric oxygen and radiotherapy: a MRC trial in carcinoma of the cervix, Brit. J. Radiol. 51:879 (1978).PubMedCrossRefGoogle Scholar
  20. 20.
    C. Rimondi, Metronidazole: a radiosensitizer of the hypoxic cells, in: “Bladder Tumors and Other Topics in Urological Oncology”, M. Pavone Macaluso, P.H. Smith and F. Edsmyr, eds., Plenum Press, New York and London (1980).Google Scholar
  21. 21.
    J. Denekamp, N. J. McNally, J. F. Fowler and M. C. Joiner, Misonidazole in fractionated radiotherapy: are many small fractions best? Brit. J. Radiol. 53 (1980) in press.Google Scholar
  22. 22.
    J. F. Fowler, New horizons in radiation oncology, Brit. J. Radiol. 52:523 (1979).PubMedCrossRefGoogle Scholar
  23. 23.
    J. F. Fowler, In vivo radiosensitization: principles and methods of study, in: “Radiosensitizers in Hypoxic Cells”, A. Breccia, C. Rimondi and G. E. Adams, Elsevier North Holland (1979).Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • C. Rimondi
    • 1
  1. 1.Department of RadiotherapyMalpighi HospitalBolognaItaly

Personalised recommendations